DILTZAC

Post-LOE

diltiazem hydrochloride

Ichnos Glenmark Innovation

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Feb 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTZAC (diltiazem hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology the therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for hypertension, chronic stable angina, angina due to coronary artery spasm. First approved in 2006.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Mechanisms of Action Hypertension: Diltiazem produces its antihypertensive effect…

Worked on DILTZAC at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DILTZAC

Mechanism of Action

Indications (3)